Top Markets
#1 Seeker Seeker +49.88%
#2 Helium Helium +43.34%
#3 TENDIES TENDIES +31.18%
#4 Pons Pons +26.01%
#5 pipedog pipedog +21.90%
#6 Zylo Ecosystem Zylo Ecosystem +21.65%
#7 Bounce Bounce +19.30%
#8 UnifAI Network UnifAI Network +18.93%
#9 ZKsync ZKsync +14.73%
#10 Zora Zora +14.06%
Coin of the day
Seeker Seeker
Setări
Limbă
ROMâNă
Monedă
USD
Temă
Poseida Therapeutics, Inc. Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc.

PSTX
Rang în acțiuni #10560
Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical... Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies. For instance, P-PSMA-101, an autologous CAR-T cell therapy, is currently undergoing Phase I clinical trials for individuals battling metastatic castrate-resistant prostate cancer (mCRPC). Additionally, Poseida is progressing two other CAR-T candidates through Phase I: P-BCMA-ALLO1 targets relapsed/refractory multiple myeloma, while P-MUC1C-ALLO1 is designed to address a variety of solid tumors, such as breast, ovarian, and other epithelial-derived malignancies. The company is further exploring allogeneic (off-the-shelf) CAR-T approaches with candidates like P-CD19CD20-ALLO1, aimed at B cell malignancies and certain autoimmune conditions, and P-BCMACD19-ALLO1, which is in preclinical development for multiple myeloma. Another allogeneic CAR-T, P-PSMA-ALLO1, is also being developed for mCRPC. Beyond cell therapies, Poseida's portfolio includes clinical-stage liver-directed gene therapies, specifically P-OTC-101 and P-FVIII-101, alongside other exploratory allogeneic dual CAR candidates. Collaborative efforts include a research and licensing agreement with Takeda Pharmaceutical Company Limited.
Preț acțiune
$9.50
Ultima sincronizare: 2025-01-08
Capitalizare de piață
$819.52M
Schimbare (1 zi)
0.00%
Schimbare (1 an)
0.00%
Țară
US
Tranzacționează Poseida Therapeutics, Inc. (PSTX)

Categorie

Healthcare
Venituri pentru Poseida Therapeutics, Inc. (PSTX)
Venituri în Sep 2024 TTM: $150.86M
Conform celor mai recente rapoarte financiare ale Poseida Therapeutics, Inc., venitul actual al companiei (TTM) este $150.86M. În anul 2022, compania a avut un venit de $130.36M o creștere față de venitul din anul 2021, care a fost de $31.24K. Venitul reprezintă suma totală generată de o companie din vânzarea de bunuri sau servicii. Spre deosebire de profit, cheltuielile nu sunt scăzute.
Istoricul veniturilor pentru Poseida Therapeutics, Inc. din 2016 până în 2026
Venituri la sfârșitul fiecărui an
An Venituri Schimbă
2026 (TTM) $150.86M 133.15%
2023 $64.70M -50.37%
2022 $130.36M 417,217.08%
2021 $31.24K 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 -100.00%
2017 $2.99M -69.44%
2016 $9.77M 0.00%
Venituri pentru companii similare sau concurente
Companie Venituri Diferență de venituri Țara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 8,268.33%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 3,891.36%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B 10,336.52%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B 1,376.89%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH